ArticleAIDS (London, England)2017
Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.
Article in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Association of state medicaid prescription cap policies with trajectories of buprenorphine use for opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Characterizing disparities in the HIV care continuum among U.S. transgender and cisgender Medicare beneficiaries, 2008-2017.AIDS care · 2025Article
- Engagement and retention in HIV care in rural Southern U.S. using an All-Payer Claims Database.PloS one · 2025Article
- Antiretroviral Therapy Use Was Not Associated with Stillbirth or Preterm Birth in an Analysis of U.S. Medicaid Pregnancies to Persons with HIV.Women's health reports (New Rochelle, N.Y.) · 2023Article
- Use of antiretroviral therapy in nursing home residents with HIV.Journal of the American Geriatrics Society · 2022Article
- Use of Antiretroviral Therapy for a US Medicaid Enrolled Pediatric Cohort with HIV.AIDS and behavior · 2021Article
- Performance of a short, self-report adherence scale in a probability sample of persons using HIV antiretroviral therapy in the United States.AIDS (London, England) · 2020Article
- Factors Associated With Antiretroviral Therapy Reinitiation in Medicaid Recipients With Human Immunodeficiency Virus.The Journal of infectious diseases · 2020Article
- Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.AIDS research and therapy · 2020Article
- The Quality of Nursing Homes That Serve Patients With Human Immunodeficiency Virus.Journal of the American Geriatrics Society · 2019Article
- The association of provider and practice factors with HIV antiretroviral therapy adherence.AIDS (London, England) · 2019Article
- Trends in medication adherence in HIV patients in the US, 2001 to 2012: an observational cohort study.Journal of the International AIDS Society · 2019Observational
- Trends in Comorbid Conditions Among Medicaid Enrollees With HIV.Open forum infectious diseases · 2019Article
- Trajectory of Physical Functioning Among Persons Living With HIV in Nursing Homes.Journal of the American Medical Directors Association · 2019Article
- One-year statin persistence and adherence in adults with HIV in the United States.Journal of clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveWhether the rate of HIV antiretroviral therapy (ART) persistence has improved over time in the United States is unknown. We examined ART persistence trends between 2001 and 2010, using non-HIV medications as a comparator.
methodsWe conducted a retrospective cohort study using Medicaid claims. We defined persistence as the duration of treatment from the first to the last fill date before a 90-day permissible gap and used Kaplan-Meier curves and Cox proportional hazard models to assess crude and adjusted nonpersistence. The secular trends of ART persistence in 43 598 HIV patients were compared with the secular trends of persistence with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARB), statins, and metformin in non-HIV-infected patients and subgroups of HIV patients who started these control medications while using ART.
resultsMedian time to ART nonpersistence increased from 23.9 months in 2001-2003 to 35.4 months in 2004-2006 and was not reached for those starting ART in 2007-2010. In adjusted models, ART initiators in 2007-2010 had 11% decreased hazard of nonpersistence compared with those who initiated in 2001-2003 (P < 0.001). For non-HIV patients initiating angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB), statins, and metformin, the hazard ratios for nonpersistence comparing 2007-2010 to 2001-2003 were 1.07, 0.94, and 1.02, respectively (all P < 0.001). For HIV patients initiating the three control medications, the hazard ratios of nonpersistence comparing 2007-2010 to 2001-2003 were 0.71, 0.65, and 0.63, respectively (all P < 0.001).
conclusionPersistence with ART improved between 2001 and 2010. Persistence with control medications improved at a higher rate among HIV patients using ART than HIV-negative controls.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.